Prognostic significance of myeloid immune cells and their spatial distribution in the colorectal cancer microenvironment.

BACKGROUND

Myeloid cells represent an abundant yet heterogeneous cell population in the colorectal cancer microenvironment, and their roles remain poorly understood.

METHODS

We used multiplexed immunofluorescence combined with digital image analysis to identify CD14

RESULTS

Higher intraepithelial (

CONCLUSIONS

Myeloid cell populations occur in spatially distinct distributions and exhibit divergent, subset-specific prognostic significance in colorectal cancer, with mature CD14

Informations de copyright

© Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

Déclaration de conflit d'intérêts

Competing interests: SAV reports grants from Finnish Cultural Foundation and Orion Research Foundation sr during the conduct of the study. KF reports other from Uehera Memorial Foundation (overseas scholarship) during the conduct of the study. ATC reports grants and personal fees from Bayer Pharma AG and personal fees from Pfizer Inc. and Boehringer Ingelheim outside the submitted work. RN is currently an employee and shareholder of Pfizer Inc. She contributed to this study before she was employed by Pfizer Inc. CSF reports consulting role for Agios, Amylin Pharmaceuticals, Astra-Zeneca, Bain Capital, CytomX Therapeutics, Daiichi-Sankyo, Eli Lilly, Entrinsic Health, Evolveimmune Therapeutics, Genentech, Merck, Taiho, and Unum Therapeutics; he also serves as a Director for CytomX Therapeutics and owns unexercised stock options for CytomX and Entrinsic Health; he is a cofounder of Evolveimmune Therapeutics and has equity in this private company; he has provided expert testimony for Amylin Pharmaceuticals and Eli Lilly. JAM reports personal fees from COTA Healthcare and Taiho Pharmaceutical (for NCCN Grant Review Panel) outside the submitted work. MG reports grants from Bristol-Myers Squibb, Merck, and Servier outside the submitted work. JAN reports grants from NanoString and Illumina outside the submitted work. The other authors declare that they have no conflicts of interest.